A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of RAY1216 Tablets in Patients With Mild to Moderate SARS-CoV-2 Infection

Guangdong Raynovent Biotech Co., Ltd1 site in 1 country1,359 target enrollmentNovember 12, 2022

ConditionsMild to Moderate COVID-19

InterventionsRAY1216 Placebo

DrugsRAY1216 Placebo

Overview

Phase: Phase 3
Intervention: RAY1216
Conditions: Mild to Moderate COVID-19
Sponsor: Guangdong Raynovent Biotech Co., Ltd
Enrollment: 1359
Locations: 1
Primary Endpoint: Time to sustained clinical recovery of 11 COVID-19 symptoms
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection. The total study duration is up to 28 days.

Registry

clinicaltrials.gov

Start Date

November 12, 2022

End Date

March 28, 2023

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Guangdong Raynovent Biotech Co., Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions.
•Participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures.
•Male or female participants aged 18-75 (including 18 and 75 years old).
•Confirmed SARS-CoV-2 infection 120 hours prior to randomization.
•Initial onset of COVID-19 symptoms/signs within 48 hours before randomization.
•Fertile participants must agree to take effective contraceptive measures.

Exclusion Criteria

•Patients with severe or critical COVID-19 who currently require hospitalization, or patients who are expected to develop into severe or critical disease and require hospitalization within 48h after randomization.
•Difficulty swallowing or a history of gastrointestinal diseases that seriously affect drug absorption.
•Active liver disease, or obvious abnormal liver function (ALT or AST ≥ 3ULN, or total bilirubin ≥ 2ULN).
•WBC \>1ULN, or NEU \<0.5ⅹ109/L.
•Receiving dialysis or have known moderate to severe renal impairment (eGFR\<60mL/min/1.73m2).
•Other suspected or confirmed systemic infections.
•Current or expected use of strong CYP3A4 inducers, inhibitors or medications that are highly dependent on CYP3A4 or CYP2C19 for clearance.
•Prior or anticipated receipt of any vaccine within 28 days prior to enrollment and during study period.
•Use of antivirals against SARS-CoV-2 within 7 days prior to enrollment.
•Weight≤40kg.

Arms & Interventions

RAY1216

Participants received 400mg RAY1216 tablet orally three times daily for 5 days.

Intervention: RAY1216

Placebo

Participants received 400mg placebo orally three times daily for 5 days.

Intervention: Placebo

Outcomes

Primary Outcomes

Time to sustained clinical recovery of 11 COVID-19 symptoms

Time Frame: Day 1 through Day 29

The time from the start of treatment to the time when 11 COVID-19 symptoms get scores of 0 for three consecutive days.

Secondary Outcomes

Proportion of participants who experience hospitalization or death cause by progression to severe disease(Day 1 through Day 29)
Proportion of participants who experience COVID-19 related hospitalization or death from any cause(Day 1 through Day 29)
SARS-CoV-2 viral shedding time in nasopharyngeal swabs(baseline, Day 4, Day 6, Day 10, Day 15)
Proportion of participants who are negative for SARS-CoV-2 nucleic acid test(baseline, Day 4, Day 6, Day 10, Day 15)
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)(Day 1 through Day 29)
Proportion of participants in clinical recovery/remission(Day 1 through Day 29)
Time to sustained clinical recovery of COVID-19 respiratory and systemic symptoms(Day 1 through Day 29)
Proportion of participants who experience death from any cause(Day 1 through Day 29)
Time to sustained clinical recovery of each COVID-19 targeted symptoms(Day 1 through Day 29)
Change of viral load compared to the baseline(baseline, Day 4, Day 6, Day 10, Day 15)
Time to clinical sustained remission(Day 1 through Day 29)
Time to sustained clinical recovery of 10 COVID-19 symptoms except cough(Day 1 through Day 29)